Advances in mouse models of prostate cancer

Expert Reviews in Molecular Medicine

Volumn 10, Issue 16, 2008, Pages

  Ahmad, Imran ^a,b   Sansom, Owen J ^a   Leung, Hing Y ^a,b  

^a BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^b NHS GREATER GLASGOW AND CLYDE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALPHA TOCOPHEROL; ANGIOSTATIN; ANTIANDROGEN; CELECOXIB; EFLORNITHINE; ENDOSTATIN; EVEROLIMUS; FIBROBLAST GROWTH FACTOR 2; FLUTAMIDE; GENISTEIN; GRAPE SEED EXTRACT; GREEN TEA EXTRACT; KERATINOCYTE GROWTH FACTOR; LYCOPENE; NEXRUTINE; NONSTEROID ANTIINFLAMMATORY AGENT; OSU 03012; PARVOVIRUS VECTOR; PHELLODENDRON AMURENSE EXTRACT; PHOSPHOTRANSFERASE INHIBITOR; POLYPHENOL DERIVATIVE; PURINE NUCLEOSIDE PHOSPHORYLASE; RAPAMYCIN; RESVERATROL; RETINOIC ACID; SELENIUM; SIRTUIN 1; TARENFLURBIL; UNINDEXED DRUG; ANDROGEN; ANDROGEN RECEPTOR;

ADVANCED CANCER; ANIMAL GENETICS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOLUMINESCENCE; CANCER GROWTH; CANCER INVASION; CANCER MODEL; CANCER MORTALITY; CANCER SURVIVAL; CARCINOGENESIS; CELL CYCLE REGULATION; CELL PROLIFERATION; CLINICAL FEATURE; DIET THERAPY; DNA METHYLATION; DOWN REGULATION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG TOLERABILITY; EXPERIMENTAL ANIMAL; GENE DELETION; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE LOSS; GENE MUTATION; GENE OVEREXPRESSION; GENE TARGETING; GENE THERAPY; GENETIC ANALYSIS; HUMAN; IMMUNOTHERAPY; IN VIVO STUDY; METASTASIS; NONHUMAN; ONCOGENE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATE CARCINOGENESIS; PROSTATIC INTRAEPITHELIAL NEOPLASIA; RNA TRANSLATION; STANDARDIZATION; TRANSGENE; TRANSGENIC ANIMAL; TUMOR SUPPRESSOR GENE; UPREGULATION; VIRAL GENE DELIVERY SYSTEM; VIRUS ONCOGENE; ADENOCARCINOMA; ANIMAL; COCARCINOGENESIS; DISEASE MODEL; DOG; DRUG SCREENING; GENETICS; HISTOLOGY; MALE; MOUSE; MOUSE MUTANT; NEOPLASM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSTATE; PROSTATE TUMOR; RAT; REVIEW; TRANSGENIC MOUSE;

ADENOCARCINOMA; ANDROGENS; ANIMALS; COCARCINOGENESIS; DISEASE MODELS, ANIMAL; DOGS; DRUG SCREENING ASSAYS, ANTITUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; MALE; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; NEOPLASMS, HORMONE-DEPENDENT; ONCOGENES; PROMOTER REGIONS (GENETICS); PROSTATE; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; RATS; RECEPTORS, ANDROGEN;

EID: 45149130887     PISSN: 14623994     EISSN: 14623994     Source Type: Journal    
DOI: 10.1017/S1462399408000689     Document Type: Article

References (157)

1. Abate-Shen, C. and Shen, M.M. (2000) Molecular genetics of prostate cancer. Genes Dev 14, 2410-2434
2. Guilbault, C. et al. (2007) Cystic fibrosis mouse models. Am J Respir Cell Mol Biol 36, 1-7
3. Dunning, WE (1963) Prostate cancer in the rat. Natl Cancer Inst Monogr 12, 351-369
4. Isaacs, J.T. et al. (1980) Concepts in prostatic cancer biology: Dunning R-3327 H, HI, and AT tumors. Prog Clin Biol Res 37, 311-323
5. Aquilina, J.W. et al. (1998) High grade prostatic intraepithelial neoplasia in military working dogs with and without prostate cancer. Prostate 36, 189-193
6. Navone, N.M. et al. (1998) Model systems of prostate cancer: Uses and limitations. Cancer Metastasis Rev 17, 361-371
7. Shappell, S.B. et al. (2004) Prostate pathology of genetically engineered mice: Definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res 64, 2270-2305
8. Kim, M.J. et al. (2002) Nkx3.1 mutant mice recapitulate early stages of prostate carcinogenesis. Cancer Res 62, 2999-3004
9. Garabedian, E.M., Humphrey, P.A. and Gordon, J.I. (1998) A transgenic mouse model of metastatic prostate cancer originating from neuroendocrine cells. Proc Natl Acad Sci U S A 95, 15382-15387
10. Masumori, N. et al. (2001) A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential. Cancer Res 61, 2239-2249
11. Abate-Shen, C. and Shen, M.M. (2002) Mouse models of prostate carcinogenesis. Trends Genet 18, S1-S5
12. Povrell, W.C. et al. (2003) Mouse strains for prostate tumorigenesis based on genes altered in human prostate cancer. Curr Drug Targets 4, 263-279
13. Greenberg, N.M. et al. (1995) Prostate cancer in a transgenic mouse. Proc Natl Acad Sci U S A 92, 3431-3443
14. Gingrich, J.R. et al. (1997) Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res 57, 4687-4691
15. Kasper, S. et al. (1998) Development, progression, and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice: A model for prostate cancer. Lab Invest 78, i-xv
16. Klezovitch, O. et al. (2004) Hepsin promotes prostate cancer progression and metastasis. Cancer Cell 6, 185-195
17. Roy-Burman, P. et al. (2004) Genetically defined mouse models that mimic natural aspects of human prostate cancer development. Endocr Relat Cancer 11, 225-254
18. Stanbrough, M. et al. (2001) Prostatic intraepithelial neoplasia in mice expressing an androgen receptor transgene in prostate epithelium. Proc Natl Acad Sci U S A 98, 10823-10828
19. Scherl, A. et al. (2004) Prostatic intraepithelial neoplasia and intestinal metaplasia in prostates of probasin-RAS transgenic mice. Prostate 59, 448-459
20. Konno-Takahashi, N. et al. (2004) Engineered FGF-2 expression induces glandular epithelial hyperplasia in the murine prostatic dorsal lobe. Eur Urol 46, 126-132
21. Polnaszek, N. et al. (2003) Fibroblast growth factor 2 promotes tumor progression in an autochthonous mouse model of prostate cancer. Cancer Res 63, 5754-5760
22. Foster, B.A. et al. (2002) Enforced expression of FGF-7 promotes epithelial hyperplasia whereas a dominant negative FGFR2iiib promotes the emergence of neuroendocrine phenotype in prostate glands of transgenic mice. Differentiation 70, 624-632
23. Song, Z. et al. (2000) The effect of fibroblast growth factor 8, isoform b, on the biology of prostate carcinoma cells and their interaction with stromal cells. Cancer Res 60, 6730-6736
24. Song, Z. et al. (2002) Fibroblast growth factor 8 isoform B overexpression in prostate epithelium: A new mouse model for prostatic intraepithelial neoplasia. Cancer Res 62, 5096-5105
25. Freeman, K.W. et al. (2003) Inducible prostate intraepithelial neoplasia with reversible hyperplasia in conditional FGFR1-expressing mice. Cancer Res 63, 8256-8263
26. Jin, C. et al. (2003) Cooperation between ectopic FGFR1 and depression of FGFR2 in induction of prostatic intraepithelial neoplasia in the mouse prostate. Cancer Res 63, 8784-8790
27. Kindblom, J. et al. (2003) Prostate hyperplasia in a transgenic mouse with prostate-specific expression of prolactin. Endocrinology 144, 2269-2278
28. Shim, E.H. et al. (2003) Expression of the F-box protein SKP2 induces hyperplasia, dysplasia, and low-grade carcinoma in the mouse prostate. Cancer Res 63, 1583-1588
29. Majumder, P. K. et al. (2003) Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: The MPAKT model. Proc Natl Acad Sci U S A 100, 7841-7846
30. Ellwood-Yen, K. et al. (2003) Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 4, 223-238
31. Duan, W et al. (2005) Knockin of SV40 Tag oncogene in a mouse adenocarcinoma of the prostate model demonstrates advantageous features over the transgenic model. Oncogene 24, 1510-1524
32. Gabril, M.Y. et al. (2002) Prostate targeting: PSP94 gene promoter/ enhancer region directed prostate tissue-specific expression in a transgenic mouse prostate cancer model. Gene Ther 9, 1589-1599
33. Kelavkar, U.P. et al. (2004) Overexpression of 12/15-lipoxygenase, an ortholog of human 15-lipoxygenase-1, in the prostate tumors of TRAMP mice. Neoplasia 6, 821-830
34. Kelavkar, U.P. et al. (2006) Conditional expression of human 15-lipoxygenase-1 in mouse prostate induces prostatic intraepithelial neoplasia: The FLiMP mouse model. Neoplasia 8, 510-522
35. Shappell, S.B. et al. (2003) Elevated expression of 12/15-lipoxygenase and cyclooxygenase-2 in a transgenic mouse model of prostate carcinoma. Cancer Res 63, 2256-2267
36. Abdulkadir, S.A. et al. (2002) Conditional loss of Nkx3.1 in adult mice induces prostatic intraepithelial neoplasia. Mol Cell Biol 22, 1493-1503
37. Bhatia-Gaur, R. et al. (1999) Roles for Nkx3.1 in prostate development and cancer. Genes Dev 13, 966-977
38. Maddison, L.A. et al. (2004) Conditional deletion of Rb causes early stage prostate cancer. Cancer Res 64, 6018-6025
39. Krege, J.H. et al. (1998) Generation and reproductive phenotypes of mice lacking estrogen receptor beta. Proc Natl Acad Sci U S A 95, 15677-15682
40. Prins, G.S. et al. (2001) Estrogen imprinting of the developing prostate gland is mediated through stromal estrogen receptor alpha: Studies with alphaERKO and betaERKO mice. Cancer Res 61, 6089-6097
41. Weihua, Z. et al. (2001) A role for estrogen receptor beta in the regulation of growth of the ventral prostate. Proc Natl Acad Sci U S A 98, 6330-6335
42. Trotman, L.C. et al. (2003) Pten dose dictates cancer progression in the prostate. PLoS Biol 1, e59.
43. Wang, S. et al. (2003) Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 4, 209-221
44. Bruxvoort, K.J. et al. (2007) Inactivation of Apc in the mouse prostate causes prostate carcinoma. Cancer Res 67, 2490-2496
45. Abdulkadir, S.A. (2005) Mechanisms of prostate tumorigenesis: Roles for transcription factors Nkx.1 and Egr1. Ann N Y Acad Sci 1059, 33-40
46. Di Cristofano, A. et al. (2001) Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nat Genet 27, 222-224
47. You, M.J. et al. (2002) Genetic analysis of Pten and Ink4a/Arf interactions in the suppression of tumorigenesis in mice. Proc Natl Acad Sci U S A 99, 1455-1460
48. Kwabi-Addo, B. et al. (2001) Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression. Proc Natl Acad Sci U S A 98, 11563-11568
49. Kim, M.J. et al. (2002) Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis. Proc Natl Acad Sci U S A 99, 2884-2889
50. Chen, M.L. et al. (2006) The deficiency of Akt1 is sufficient to suppress tumor development in Pten +/- mice. Genes Dev 20, 1569-1574
51. Zhong, C. et al. (2006) Cooperation between FGF8b overexpression and PTEN deficiency in prostate tumorigenesis. Cancer Res 66, 2188-2194
52. Zhou, Z. et al. (2006) Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer. Cancer Res 66 7889-7898
53. Rennie, P.S. et al. (1993) Characterization of two cis- acting DNA elements involved in the androgen regulation of the probasin gene. Mol Endocrinol 7, 23-36
54. Kasper, S. et al. (1994) Cooperative binding of androgen receptors to two DNA sequences is required for androgen induction of the probasin gene. J Biol Chem 269, 31763-31769
55. Brookes, D.E. et al. (1998) Relative activity and specificity of promoters from prostate-expressed genes. Prostate 35, 18-26
56. Yan, Y. et al. (1997) Large fragment of the probasin promoter targets high levels of transgene expression to the prostate of transgenic mice. Prostate 32, 129-139
57. Zhang, J. et al. (2000) A small composite probasin promoter confers high levels of prostate-specific gene expression through regulation by androgens and glucocorticoids in vitro and in vivo. Endocrinology 141, 4698-4710
58. Wu, X. et al. (2001) Generation of a prostate epithehal cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mech Dev 101, 61-69
59. Shibata, M.A. et al. (1996) Progression of prostatic intraepithelial neoplasia to invasive carcinoma in C3(1)/SV40 large T antigen transgenic mice: Histopathological and molecular biological alterations. Cancer Res 56, 4894-4903
60. Skalnik, D.G. et al. (1991) Restriction of neuroblastoma to the prostate gland in transgenic mice. Mol Cell Biol 11, 4518-4527
61. Cussenot, O. et al. (1994) Immunocytochemical comparison of cultured normal epithelial prostatic cells with prostatic tissue sections. Exp Cell Res 214, 83-92
62. Leav, I. et al. (1996) Androgen receptor expression in prostatic dysplasia (prostatic intraepithelial neoplasia) in the human prostate: an immunohistochemical and in situ hybridization study. Prostate 29, 137-145
63. Feldman, B.J. and Feldman, D. (2001) The development of androgen-independent prostate cancer. Nat Rev Cancer 1, 34-45
64. Chen, C.D. et al. (2004) Molecular determinants of resistance to antiandrogen therapy. Nat Med 10, 33-39
65. McKeehan, W.L., Wang, F. and Kan, M. (1998) The heparan sulfate-fibroblast growth factor family: Diversity of structure and function. Prog Nucleic Acid Res Mol Biol 59, 135-176
66. Basilico, C. and Moscatelli, D. (1992) The FGF family of growth factors and oncogenes. Adv Cancer Res 59, 115-165
67. Cunha, G.R. et al. (1992) Normal and abnormal development of the male urogenital tract. Role of androgens, mesenchymal-epithelial interactions, and growth factors. J Androl 13, 465-475
68. Heer, R. et al. (2004) Fibroblast growth factor 17 is over-expressed in human prostate cancer. J Pathol 204, 578-586
69. Ozen, M. et al. (2001) Role of fibroblast growth factor receptor signaling in prostate cancer cell survival. J Natl Cancer Inst 93, 1783-1790
70. Ropiquet, F. et al. (2000) Increased expression of fibroblast growth factor 6 in human prostatic intraepithelial neoplasia and prostate cancer. Cancer Res 60, 4245-4250
71. Foster, B.A., Kaplan, P.J. and Greenberg, N.M. (1999) Characterization of the FGF axis and identification of a novel FGFR1iiic isoform during prostate cancer progression in the TRAMP model. Prostate Cancer Prostatic Dis 2, 76-82
72. Rubin, J.S. et al. (1995) Keratinocyte growth factor. Cell Biol Int 19, 399-411
73. Sugimura, Y. et al. (1996) Keratinocyte growth factor (KGF) can replace testosterone in the ductal branching morphogenesis of the rat ventral prostate. Int J Dev Biol 40, 941-951
74. McGarvey, T.W. and Stearns, M.E. (1995) Keratinocyte growth factor and receptor mRNA expression in benign and malignant human prostate. Exp Mol Pathol 63, 52-62
75. Foster, B.A. et al. (1997) Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res 57, 3325-3330
76. Huss, W.J. et al. (2003) Differential expression of specific FGF ligand and receptor isoforms during angiogenesis associated with prostate cancer progression. Prostate 54, 8-16
77. Dorkin, T.J. et al. (1999) FGF8 over-expression in prostate cancer is associated with decreased patient survival and persists in androgen independent disease. Oncogene 18, 2755-2761
78. Franke, T.F. et al. (1997) Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate. Science 275, 665-668
79. Wu, X. et al. (1998) The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci U S A 95, 15587-15591
80. Nesbit, C.E., Tersak, J.M. and Prochownik, E.V. (1999) MYC oncogenes and human neoplastic disease. Oncogene 18, 3004-3016
81. Gabril, M. et al. (2004) Characterization of initiation of angiogenesis in early stages of prostate adenocarcinoma development and progression in a transgenic murine model. Urology 64, 1233-1237
82. Huizen, I.V. et al. (2005) Establishment of a serum tumor marker for preclinical trials of mouse prostate cancer models. Clin Cancer Res 11, 7911-7919
83. Capecchi, M.R. (1994) Targeted gene replacement. Sci Am 270, 52-59
84. Copp, A.J. (1995) Death before birth: Clues from gene knockouts and mutations. Trends Genet 11, 87-93
85. Nagy, A. (2000) Cre recombinase: The universal reagent for genome tailoring. Genesis 26, 99-109
86. Sauer, B. and Henderson, N. (1988) Site-specific DNA recombination in mammalian cells by the Cre recombinase of bacteriophage P1. Proc Natl Acad Sci U S A 85, 5166-5170
87. Soriano, P. (1999) Generalized lacZ expression with the ROSA26 Cre reporter strain. Nat Genet 21, 70-71
88. Bowen, C. et al. (2000) Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression. Cancer Res 60, 6111-6115
89. Dong, J.T. (2001) Chromosomal deletions and tumor suppressor genes in prostate cancer. Cancer Metastasis Rev 20, 173-193
90. Bieberich, C.J. et al. (1996) Prostate-specific and androgen-dependent expression of a novel homeobox gene. J Biol Chem 271, 31779-31782
91. Bethel, C.R. and Bieberich, C.J. (2007) Loss of Nkx3.1 expression in the transgenic adenocarcinoma of mouse prostate model. Prostate 67, 1740-1750
92. Tanaka, M. et al. (2000) Nkx3.1, a murine homolog of Ddrosophila bagpipe, regulates epithelial ductal branching and proliferation of the prostate and palatine glands. Dev Dyn 219, 248-260
93. Dahia, P.L. (2000) PTEN, a unique tumor suppressor gene. Endocr. Relat Cancer 7, 115-129
94. Suzuki, H. et al. (1998) Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res 58, 204-209
95. Di Cristofano, A. et al. (1998) Pten is essential for embryonic development and tumour suppression. Nat Genet 19, 348-355
96. Podsypanina, K. et al. (1999) Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci U S A 96, 1563-1568
97. Stambolic, V. et al. (2000) High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten +/- mice. Cancer Res 60, 3605-3611
98. Mundy, G.R. (2002) Metastasis to bone: Causes, consequences and therapeutic opportunities. Nat Rev Cancer 2, 584-593
99. Brewster, S.F., Browne, S. and Brown, K.W. (1994) Somatic allelic loss at the DCC, APC, nm23-H1 and p53 tumor suppressor gene loci in human prostatic carcinoma. J Urol 151, 1073-1077
100. Phillips, S.M. et al. (1994) Loss of heterozygosity of the retinoblastoma and adenomatous polyposis susceptibility gene loci and in chromosomes 10p, 10q and 16q in human prostate cancer. Br J Urol 73, 390-395
101. Jeronimo, C. et al. (2004) A quantitative promoter methylation profile of prostate cancer. Clin. Cancer Res 10, 8472-8478
102. Yegnasubramanian, S. et al. (2004) Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 64, 1975-1986
103. Sharpless, N.E. and DePinho, R.A. (1999) The INK4A/ARF locus and its two gene products. Curr Opin Genet Dev 9, 22-30
104. Burri, N. et al. (2001) Methylation silencing and mutations of the p14ARF and p16INK4a genes in colon cancer. Lab Invest 81, 217-229
105. Chen, Z. et al. (2005) Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436, 725-730
106. Abate-Shen, C. et al. (2003) Nkx3.1; Pten mutant mice develop invasive prostate adenocarcinoma and lymph node metastases. Cancer Res 63, 3886-3890
107. Gao, H. et al. (2006) Combinatorial activities of Akt and B-Raf/Erk signaling in a mouse model of androgen-independent prostate cancer. Proc Natl Acad Sci U S A 103, 14477-14482
108. Gao, H. et al. (2006) Emergence of androgen independence at early stages of prostate cancer progression in Nkx3.1; Pten mice. Cancer Res 66, 7929-7933
109. Majumder, P.K. et al. (2004) mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 10, 594-601
110. Wechter, W.J. et al. (2000) E-7869 (R-flurbiprofen) inhibits progression of prostate cancer in the TRAMP mouse. Cancer Res 60, 2203-2208
111. Gupta, S. et al. (2004) Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. Cancer Res 64, 3334-3343
112. Narayanan, B.A. et al. (2004) Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model. Clin Cancer Res 10, 7727-7737
113. Abdulkadir, S.A. and Kim, J. (2005) Genetically engineered murine models of prostate cancer: Insights into mechanisms of tumorigenesis and potential utility. Future Oncol 1, 351-360
114. Sargeant, A.M. et al. (2007) Chemopreventive and bioenergetic signaling effects of PDK1/Akt pathway inhibition in a transgenic mouse model of prostate cancer. Toxicol Pathol 35, 549-561
115. Wang, J., Eltoum, I.E. and Lamartiniere, C.A. (2007) Genistein chemoprevention of prostate cancer in TRAMP mice. J Carcinog 6, 3
116. Chanvitayapongs, S., Draczynska-Lusiak, B. and Sun, A.Y. (1997) Amelioration of oxidative stress by antioxidants and resveratrol in PC12 cells. Neuroreport 8, 1499-1502
117. Harper, C.E. et al. (2007) Resveratrol suppresses prostate cancer progression in transgenic mice. Carcinogenesis 28, 1946-1953
118. Gupta, S. et al. (2001) Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols. Proc Natl Acad Sci USA 98, 10350-10355
119. Gupta, S. et al. (2000) Chemoprevention of prostate carcinogenesis by alpha-difluoromethylornithine in TRAMP mice. Cancer Res 60, 5125-5133
120. Huss, W.J. et al. (2004) Retinoic acid slows progression and promotes apoptosis of spontaneous prostate cancer. Prostate 61, 142-152
121. Raina, K. et al. (2007) Oral grape seed extract inhibits prostate tumor growth and progression in TRAMP mice. Cancer Res 67, 5976-5982
122. Venkateswaran, V. et al. (2004) Antioxidants block prostate cancer in lady transgenic mice. Cancer Res 64, 5891-5896
123. Raghow, S. et al. (2000) Efficacious chemoprevention of primary prostate cancer by flutamide in an autochthonous transgenic model. Cancer Res 60, 4093-4097.
124. Raghow, S. et al. (2002) Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model. Cancer Res 62, 1370-1376
125. Mori, H. et al. (1995) Principle of the bark of Phellodendron amurense to suppress the cellular immune response: Effect of phellodendrine on cellular and humoral immune responses. Planta Med 61, 45-49
126. Kumar, A.P. et al. (2007) Akt/cAMP-responsive element binding protein/ cyclin D1 network: A novel target for prostate cancer inhibition in transgenic adenocarcinoma of mouse prostate model mediated by Nexrutine, a Phellodendron amurense bark extract. Clin Cancer Res 13, 2784-2794
127. Hurwitz, A.A. et al. (2000) Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res 60, 2444-2448
128. Linsley, P.S. et al. (1991) CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 174, 561-569
129. Martiniello-Wilks, R. et al. (2003) Application of the transgenic adenocarcinoma mouse prostate (TRAMP) model for pre-clinical therapeutic studies. Anticancer Res 23, 2633-2642
130. Isayeva, T. et al. (2007) Effects of sustained antiangiogenic therapy in multistage prostate cancer in TRAMP model. Cancer Res 67, 5789-5797
131. Kaeberlein, M., McVey, M. and Guarente, L. (1999) The SIR2/3/4 complex and SIR2 alone promote longevity in Saccharomyces cerevisiae by two different mechanisms. Genes Dev 13, 2570-2580
132. Brunet, A. et al. (2004) Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 303, 2011-2015
133. Cohen, H.Y. et al. (2004) Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science 305, 390-392
134. Huffman, D.M. et al. (2007) SIRT1 is significantly elevated in mouse and human prostate cancer. Cancer Res 67, 6612-6618
135. Bastian, P.J. et al. (2004) Molecular biomarker in prostate cancer: The role of CpG island hypermethylation. Eur Urol 46, 698-708
136. Patra, S.K. et al. (2002) DNA methyltransferase and demethylase in human prostate cancer. Mol. Carcinog. 33, 163-171
137. McCabe, M.T. et al. (2006) Inhibition of DNA methyltransferase activity prevents tumorigenesis in a mouse model of prostate cancer. Cancer Res 66, 385-392
138. Weissleder, R. (2002) Scaling down imaging: Molecular mapping of cancer in mice. Nat Rev Cancer 2, 11-18
139. Massoud, T.F. and Gambhir, S.S. (2003) Molecular imaging in living subjects: Seeing fundamental biological processes in a new light. Genes Dev 17, 545-580
140. Choy, G. et al. (2003) Comparison of noninvasive fluorescent and bioluminescent small animal optical imaging. Biotechniques 35, 1022-1030
141. Hsieh, C.L. et al. (2005) A luciferase transgenic mouse model: visualization of prostate development and its androgen responsiveness in live animals. J Mol Endocrinol 35, 293-304
142. Lyons, S.K. et al. (2006) Noninvasive bioluminescence imaging of normal and spontaneously transformed prostate tissue in mice. Cancer Res 66, 4701-4707
143. Ellwood-Yen, K., Wongvipat, J. and Sawyers, C. (2006) Transgenic mouse model for rapid pharmacodynamic evaluation of antiandrogens. Cancer Res 66, 10513-10516
144. Liao, C.P. et al. (2007) Mouse models of prostate adenocarcinoma with the capacity to monitor spontaneous carcinogenesis by bioluminescence or fluorescence. Cancer Res 67, 7525-7533
145. Nastiuk, K.L. et al. (2007) In vivo MRI volumetric measurement of prostate regression and growth in mice. BMC Urol 7, 12
146. Feil, R. et al. (1996) Ligand-activated site-specific recombination in mice. Proc Natl Acad Sci U S A 93, 10887-10890
147. Indra, A.K. et al. (1999) Temporally-controlled site-specific mutagenesis in the basal layer of the epidermis: Comparison of the recombinase activity of the tamoxifen-inducible Cre-ER(T) and Cre-ER(T2) recombinases. Nucleic Acids Res 27, 4324-4327
148. Jonkers, J. and Berns, A. (2002) Conditional mouse models of sporadic cancer. Nat Rev Cancer 2, 251-265
149. Bex, A. et al. (2002) Controlling gene expression in the urothelium using transgenic mice with inducible bladder specific Cre-lox recombination. J Urol 168, 2641-2644
150. Leow, C.C., Wang, X.D. and Gao, W.Q. (2005) Novel method of generating prostate-specific Cre-LoxP gene switching via intraductal delivery of adenovirus. Prostate 65, 1-9
151. Czauderna, F. et al. (2003) Inducible shRNA expression for application in a prostate cancer mouse model. Nucleic Acids Res 31, e127
152. Oyama, N. et al. (2004) Monitoring of therapy in androgen-dependent prostate tumor model by measuring tumor proliferation. J Nucl Med 45, 519-525
153. Yang, Y.S. et al. (2006) Comparative in vitro and in vivo evaluation of two 64Cu-labeled bombesin analogs in a mouse model of human prostate adenocarcinoma. Nucl Med Biol 33, 371-380
154. Garrison, J.C. et al. (2007) In vivo evaluation and small-animal PET/CT of a prostate cancer mouse model using 64Cu bombesin analogs: side-by-side comparison of the CB-TE2A and DOTA chelation systems. J Nucl Med 48, 1327-1337
155. Bhowmick, N.A. et al. (2004) TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 303, 848-851
156. Zhao, M. et al. (2007) Monotherapy with a tumor-targeting mutant of Salmonella typhimurium cures orthotopic metastatic mouse models of human prostate cancer. Proc Natl Acad Sci U S A 104, 10170-10174
157. Zhang, L. et al. (2007) Intratumoral delivery and suppression of prostate tumor growth by attenuated Salmonella enterica serovar typhimurium carrying plasmid-based small interfering RNAs. Cancer Res 67, 5859-5864